Immuno-oncology approaches have entered clinical practice, with tremendous progress
particularly in the field of T cell-engaging therapies over the past decade. Herein, we provide …

Immune-checkpoint inhibition provides an unmatched level of durable clinical efficacy in
various malignancies. Such therapies promote the activation of antigen-specific T cells …

Advancements in adoptive cell therapy over the last four decades have revealed various
new therapeutic strategies, such as chimeric antigen receptors (CARs), which are dedicated …

Non-small cell lung cancer (NSCLC) carries a high mortality, and efficacious therapy is
lacking. Therapy using chimeric antigen receptor (CAR) T cells has been used efficaciously …

Chimeric Antigen Receptor (CAR)-T cells have great efficacy against CD19+ leukemia but
little success for solid tumors. This study explored the effectiveness of third generation anti …

Chimeric antigen receptor-T (CAR-T) cells have limited therapeutic efficacy against solid
tumors, partially due to their limited ability to reach and invade into the neoplastic foci. By …

Resident memory T (TRM) cells are a unique subset of CD8+ T cells that are present within
certain tissues and do not recirculate through the blood. Long term memory establishment …

Adoptive transfer of T‐cells is a promising therapy for many cancers. To enhance tumour
recognition by T‐cells, chimeric antigen receptors (CARs) consisting of signalling domains …

Chimeric antigen receptors (CAR) utilize costimulatory domains to enhance anti-tumor
efficacy. However, it is unclear which costimulatory domain is preferable. Therefore, the …

Aim: To determine the relationship between gene expression profile (GEP) and overall
survival (OS) by NanoString following treatment with Vigil. Patients and Methods: Recurrent …